Rapport Therapeutics (NASDAQ:RAPP) Trading Down 6% – What’s Next?

Rapport Therapeutics (NASDAQ:RAPP)’s share price was down 6% during trading on Tuesday . The stock traded as low as $22.40 and last traded at $22.56. Approximately 42,321 shares were traded during trading, a decline of 72% from the average daily volume of 153,353 shares. The stock had previously closed at $24.00.

Rapport Therapeutics Stock Up 7.7 %

The stock has a 50-day moving average of $23.19.

Institutional Investors Weigh In On Rapport Therapeutics

Institutional investors have recently made changes to their positions in the company. Values First Advisors Inc. bought a new position in Rapport Therapeutics during the 3rd quarter worth $31,000. BNP Paribas Financial Markets acquired a new position in Rapport Therapeutics during the 3rd quarter worth $34,000. SG Americas Securities LLC acquired a new position in Rapport Therapeutics during the 3rd quarter worth $101,000. Sandia Investment Management LP acquired a new position in Rapport Therapeutics during the 2nd quarter worth $116,000. Finally, MetLife Investment Management LLC acquired a new position in Rapport Therapeutics during the 3rd quarter worth $117,000.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.